Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.

Article  CAS  PubMed  Google Scholar 

Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131:1190–203.

Article  CAS  PubMed  Google Scholar 

Solomon B, Varella-Garcia M, Camidge DR. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J Thorac Oncol. 2009;4:1450–4.

Article  PubMed  Google Scholar 

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: non-small cell lung cancer. Version 5. 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed 30 July 2024.

The Japanese Lung Cancer Society. Lung cancer clinical practice guidelines. 2023. https://www.haigan.gr.jp/guideline/2023/. Accessed 30 July 2024.

Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.

Article  CAS  PubMed  Google Scholar 

Solomon BJ, Mok T, Kim D-W, Wu Y-L, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77.

Article  PubMed  Google Scholar 

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim D-W, et al. Alectinib versus crizotinib in untreated ALK -positive non–small-cell lung cancer. N Engl J Med. 2017;377:829–38.

Article  CAS  PubMed  Google Scholar 

Shaw AT, Bauer TM, De Marinis F, Felip E, Goto Y, Liu G, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N Engl J Med. 2020;383:2018–29.

Article  CAS  PubMed  Google Scholar 

Gainor JF, Dardaei L, Yoda S, Friboulet L, Leshchiner I, Katayama R, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–33.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin JJ, Riely GJ, Shaw AT. Targeting ALK: precision medicine takes on drug resistance. Cancer Discov. 2017;7:137–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olivares-Hernández A, González del Portillo E, Tamayo-Velasco Á, Figuero-Pérez L, Zhilina-Zhilina S, Fonseca-Sánchez E, et al. Immune checkpoint inhibitors in non-small cell lung cancer: from current perspectives to future treatments—a systematic review. Ann Transl Med. 2023;11:354.

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Engl J Med. 2016;375:1823–33.

Article  CAS  PubMed  Google Scholar 

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378:2078–92.

Article  CAS  PubMed  Google Scholar 

Hellmann MD, Paz-Ares L, Caro RB, Zurawski B, Kim S-W, Costa EC, et al. Nivolumab plus ipilimumab in advanced non–small-cell lung cancer. N Engl J Med. 2019;381:2020–31.

Article  CAS  PubMed  Google Scholar 

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019;30:1321–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oya Y, Kuroda H, Nakada T, Takahashi Y, Sakakura N, Hida T. Efficacy of immune checkpoint inhibitor monotherapy for advanced non-small-cell lung cancer with ALK rearrangement. Int J Mol Sci. 2020;21:2623.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Uehara Y, Hakozaki T. Immune checkpoint inhibitors for patients with gene-rearranged non-small cell lung cancer. Transl Lung Cancer Res. 2023;12:6–10.

Article  PubMed  Google Scholar 

Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021;9: e002891.

Article  PubMed  PubMed Central  Google Scholar 

Bodor JN, Bauman JR, Handorf EA, Ross EA, Clapper ML, Treat J. Real-world progression-free survival (rwPFS) and the impact of PD-L1 and smoking in driver-mutated non-small cell lung cancer (NSCLC) treated with immunotherapy. J Cancer Res Clin Oncol. 2023;149:1755–63.

Article  CAS  PubMed  Google Scholar 

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med. 2018;378:2288–301.

Article  CAS  PubMed  Google Scholar 

Kagawa Y, Wang C, Piao Y, Jin L, Tanizawa Y, Cai Z, et al. Real-world evidence of FOLFIRI combined with anti-angiogenesis inhibitors or anti-EGFR antibodies for patients with early recurrence colorectal cancer after adjuvant FOLFOX/CAPOX Therapy: a Japanese claims database study. Targ Oncol. 2024;19:575–85.

Article  Google Scholar 

Medical Data Vision. About MDV database. http://www.mdv.co.jp/. Accessed 30 July 2024.

Laurent T, Simeone J, Kuwatsuru R, Hirano T, Graham S, Wakabayashi R, et al. Context and considerations for use of two Japanese real-world databases in Japan: medical data vision and Japanese medical data center. Drugs Real World Outcomes. 2022;9:175–87.

Article  PubMed  PubMed Central  Google Scholar 

Cancer Statistics in Japan: 2023. Foundation for promotion of cancer research; 2023. https://ganjoho.jp/public/qa_links/report/statistics/pdf/cancer_statistics_2023.pdf. Accessed 5 Oct 2024.

Functional evaluation: the Barthel Index. Maryl State Med J.

Ihara Y, Sawa K, Imai T, Nonomiya Y, Shimomura Y, Ishihara A, et al. Immune checkpoint inhibitor is associated with improved survival in advanced non-small cell lung cancer occurring in patients with autoimmune disease. Biol Pharm Bull. 2024;47:454–61.

Article  CAS  PubMed  Google Scholar 

Jacob S, Rahbari K, Tegtmeyer K, Zhao J, Tran S, Helenowski I, et al. Lung cancer survival in patients with autoimmune disease. JAMA Netw Open. 2020;3: e2029917.

Article  PubMed  PubMed Central  Google Scholar 

Otto E, Culakova E, Meng S, Zhang Z, Xu H, Mohile S, et al. Overview of Sankey flow diagrams: focusing on symptom trajectories in older adults with advanced cancer. J Geriatr Oncol. 2022;13:742–6.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chia PL, Gedye C, Boutros PC, Wheatley-Price P, John T. Current and evolving methods to visualize biological data in cancer research. J Natl Cancer Inst. 2016;108:djw031.

Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30:830–8.

Article  CAS  PubMed  Google Scholar 

Jahanzeb M, Lin HM, Pan X, Yin Y, Baumann P, Langer CJ. Immunotherapy treatment patterns and outcomes among ALK-positive patients with non–small-cell lung cancer. Clin Lung Cancer. 2021;22:49–57.

Article  CAS  PubMed  Google Scholar 

R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2021. https://www.R-project.org/. Accessed 30 July 2024.

Koh J, Jang J-Y, Keam B, Kim S, Kim M-Y, Go H, et al. EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. Oncoimmunology. 2016;5: e1108514.

Article  PubMed  Google Scholar 

Hong S, Chen N, Fang W, Zhan J, Liu Q, Kang S, et al. Upregulation of PD-L1 by EML4-ALK fusion protein mediates the immune escape in ALK positive NSCLC: Implication for optional anti-PD-1/PD-L1 immune therapy for ALK-TKIs sensitive and resistant NSCLC patients. Oncoimmunology. 2016;5: e1094598.

Article  PubMed  Google Scholar 

Ota K, Azuma K, Kawahara A, Hattori S, Iwama E, Tanizaki J, et al. Induction of PD-L1 expression by the EML4-ALK oncoprotein and downstream signaling pathways in non-small cell lung cancer. Clin Cancer Res. 2015;21:4014–21.

Article  CAS  PubMed  Google Scholar 

Chae YK, Davis AA, Raparia K, Agte S, Pan A, Mohindra N, et al. Association of tumor mutational burden with